Carmeda AB`

Since the early 1970's, the search for artificial materials with passive or inert surfaces that would present no challenge to blood or other tissues has been intense. This research has met with limited success until the Carmeda® BioActive Surface (CBASTM) was invented. Now CBASTM represents the most clinically proven of all hemo-compatible surface technologies.In Sweden , the interest in heparin began with Professor Erik Jorpes who taught and worked at the Karolinska Institute in Stockholm. His interest was awakened during the 1920's when he was a guest researcher in the US. On returning to Sweden he continued the work and managed to purify heparin in 1935. His achievements led to an interest within the field among his students, and Sweden now can boast of a considerable concentration of industry and academic efforts concerning heparin and blood coagulation.
The breakthrough in surface heparinisation of artificial materials came in 1981 when Professor Olle Larm at the Swedish University of Agricultural Sciences in Uppsala invented a technique whereby heparin could be linked to different surfaces without losing its biological function. He chemically modified the heparin molecule and managed to attach them "end point" to the blood contacting surface. The heparin molecules were thereby able to interact with antithrombin and other coagulation factors in blood, and a non-thrombogenic surface was created.
In 1983, Medicarb was established to commercialise the patented invention by Prof. Larm. Since the company consisted only of chemists, a subsidiary – Carmeda - was founded in 1984 to focus exclusively on heparinising artificial surfaces for clinical use. Medicarb remained research-focused, whereas Carmeda focused on the commercial activities and was acquired by Norsk Hydro in 1986.

Contact Details: Sweden Tel: Fax: Email: info@carmeda.se WWW: www.carmeda.se/

Recent Publications by Carmeda AB`:
Cellulose thin films: degree of cellulose ordering and its influence on adhesion. Adhesion measurements have been performed with thin cellulose films using...	12th July, 2007	Carmeda AB, Kanalvagen 3B, SE-194 61 Upplands Vasby, Sweden.	Biomacromolecules. 2007 Mar;8(3):912-9. Epub 2007 Feb 24. DOI Direct Link

BioNews Results for Carmeda AB`:
Diagnostic Hybrids Announces FDA Clearance of D3(R) FastPointTM L-DFATM Influenza A/ Influenza B Virus Identif	Pharmacy Choice:  Nov 15 2009 4:54PM Matching: ab
BioInvent Signs Licensing Agreement with Daiichi Sankyo for the Discovery and Development of Therapeutic Antib	PharmiWeb:  Nov 15 2009 3:26AM Matching: ab
Axelar AB Presents the New Anticancer Agent AXL1717 at The AACR-NCI-EORTC International Conference on Molecula	KOTA Territory News:  Nov 14 2009 11:05PM Matching: ab
Axelar AB Presents the New Anticancer Agent AXL1717 at The AACR-NCI-EORTC International Conference on Molecula	KSLA:  Nov 14 2009 7:28AM Matching: ab
GM: 37 pct of US Saab dealerships to close	Research & Development:  Nov 14 2009 7:48PM Matching: ab
Promote your company here: BioNewsCast - Press Release Distribution	→View more Carmeda AB` news.

Carmeda AB` Patents:
US Patent No.	Title
6767405	Apparatus and process for coating articles
6559132	Composition comprising heparin as a non-thrombogenic surface coating agent
6461665	Process for preparing surface modification substances

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 350 times since April 2007, the link to the organisation's website has been followed 66 times

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for Carmeda AB`